β-Lactamase inhibition by avibactam in Mycobacterium abscessus

Journal of Antimicrobial Chemotherapy

Volumn 70, Issue 4, 2014, Pages 1051-1058

  Dubée, Vincent ^a,b,c   Bernut, Audrey ^d   Cortes, Mélanie ^a,b,c   Lesne, Tiffany ^d   Dorchene, Delphine ^a,b,c   Lefebvre, Anne Laure ^a,b,c   Hugonnet, Jean Emmanuel ^a,b,c   Gutmann, Laurent ^a,b,c,e   Mainardi, Jean Luc ^a,b,c,e   Herrmann, Jean Louis ^e,f   Gaillard, Jean Louis ^e,f   Kremer, Laurent ^d   Arthur, Michel ^a,b,c  

^a CENTRE DE RECHERCHE DES CORDELIERS   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c SORBONNE UNIVERSITÉ   (France)

^d UNIVERSITÉ DE MONTPELLIER   (France)

^e ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^f Laboratoire de Microbiologie   (France)

Author keywords

Cystic fibrosis; M. abscessus; Non tuberculous mycobacteria; Therapy; lactams

Indexed keywords

AMIKACIN; AMOXICILLIN; AVIBACTAM; AZTREONAM; BETA LACTAMASE; CEFALOTIN; CEFAMANDOLE; CEFOXITIN; CEFTAZIDIME; CEFTRIAXONE; CEFUROXIME; IMIPENEM; MEROPENEM; ANTIINFECTIVE AGENT; AZABICYCLO DERIVATIVE; BETA LACTAMASE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GROWTH; BACTERIAL VIABILITY; BACTERIUM ISOLATE; CARBAMOYLATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG HYDROLYSIS; EMBRYO; ENZYME INACTIVATION; ENZYME INHIBITION; GENE DELETION; HUMAN; HUMAN CELL; IN VITRO STUDY; MACROPHAGE; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIOSIS; MYCOBACTERIUM ABSCESSUS; NONHUMAN; ANIMAL; CELL LINE; DRUG EFFECTS; ENZYMOLOGY; METABOLISM; MICROBIOLOGY; MYCOBACTERIUM; MYCOBACTERIUM INFECTIONS; TREATMENT OUTCOME; ZEBRA FISH;

AMOXICILLIN; ANIMALS; ANTI-BACTERIAL AGENTS; AZABICYCLO COMPOUNDS; BETA-LACTAMASE INHIBITORS; BETA-LACTAMASES; CELL LINE; HUMANS; MACROPHAGES; MODELS, ANIMAL; MYCOBACTERIUM; MYCOBACTERIUM INFECTIONS; TREATMENT OUTCOME; ZEBRAFISH;

EID: 84926463339     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dku510     Document Type: Article

References (41)

1. Kusunoki S, Ezaki T. Proposal of Mycobacterium peregrinum sp. nov., nom. rev., and elevation of Mycobacterium chelonae subsp. abscessus (Kubica et al.) to species status: Mycobacterium abscessus comb. nov. Int J Syst Bacteriol 1992; 42: 240-5.
2. Medjahed H, Gaillard JL, Reyrat JM. Mycobacterium abscessus: a new player in the mycobacterial field. Trends Microbiol 2010; 18: 117-23.
3. Ripoll F, Pasek S, Schenowitz C et al. Non mycobacterial virulence genes in the genome of the emerging pathogen Mycobacterium abscessus. PLoS One 2009; 4: e5660.
4. Falsey RR, Kinzer MH, Hurst S et al. Cutaneous inoculation of nontuberculous mycobacteria during professional tattooing: a case series and epidemiologic study. Clin Infect Dis 2013; 57: e143-7.
5. Ryu HJ, KimWJ, Oh CH et al. Iatrogenic Mycobacterium abscessus infection associated with acupuncture: clinical manifestations and its treatment. Int J Dermatol 2005; 44: 846-50.
6. Griffith DE, Aksamit T, Brown-Elliott BA et al. An official ATS/IDSA statement:diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007; 175: 367-416.
7. Griffith DE, Girard WM, Wallace RJ Jr. Clinical features of pulmonary disease caused by rapidly growingmycobacteria. An analysis of 154 patients. Am Rev Respir Dis 1993; 147: 1271-8.
8. Koh WJ, Lee JH, Kwon YS et al. Prevalence of gastroesophageal reflux disease in patients with nontuberculous mycobacterial lung disease. Chest 2007; 131: 1825-30.
9. Nash KA, Brown-Elliott BA,Wallace RJ Jr. A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. Antimicrob Agents Chemother 2009; 53: 1367-76.
10. Choi GE, Shin SJ, Won CJ et al. Macrolide treatment for Mycobacterium abscessus and Mycobacterium massiliense infection and inducible resistance. Am J Respir Crit Care Med 2012; 186: 917-25.
11. Lavollay M, Dubée V, HeymB et al. In vitro activity of cefoxitin and imipenem against Mycobacterium abscessus complex. Clin Microbiol Infect 2014; 20: O297-300.
12. Soroka D, Dubée V, Soulier-Escrihuela O et al. Characterization of broad-spectrum Mycobacterium abscessus class A β-lactamase. J Antimicrob Chemother 2014; 69: 691-6.
13. Jarlier V, Gutmann L, Nikaido H. Interplay of cell wall barrier and β-lactamase activity determines high resistance to β-lactam antibiotics in Mycobacterium chelonae. Antimicrob Agents Chemother 1991; 35:1937-9.
14. Lavollay M, Arthur M, Fourgeaud M et al. The peptidoglycan of stationary-phase Mycobacterium tuberculosis predominantly contains cross-links generated by L,D-transpeptidation. J Bacteriol 2008; 190:4360-6.
15. Triboulet S, Dubee V, Lecoq L et al. Kinetic features of L,D-transpeptidase inactivation critical for β-lactam antibacterial activity. PLoS One 2013; 8:e67831.
16. Flores AR, Parsons LM, Pavelka MS Jr. Genetic analysis of the β-lactamases of Mycobacterium tuberculosis and Mycobacterium smegmatis and susceptibility to β-lactam antibiotics. Microbiology 2005; 151:521-32.
17. Wang F, Cassidy C, Sacchettini JC. Crystal structure and activity studies of the Mycobacterium tuberculosis β-lactamase reveal its critical role in resistance to β-lactam antibiotics. Antimicrob Agents Chemother 2006; 50: 2762-71.
18. Hugonnet JE, Tremblay LW, Boshoff HI et al. Meropenem-clavulanate is effective against extensively drug-resistant Mycobacterium tuberculosis. Science 2009; 323: 1215-8.
19. Dauby N, Muylle I, Mouchet F et al. Meropenem/clavulanate and linezolid treatment for extensively drug-resistant tuberculosis. Pediatr Infect Dis J 2011; 30: 812-3.
20. Payen MC, De Wit S, Martin C et al. Clinical use of the meropenemclavulanate combination for extensively drug-resistant tuberculosis. Int J Tuberc Lung Dis 2012; 16: 558-60.
21. Roux AL, Ray A, Pawlik A et al. Overexpression of proinflammatory TLR-2-signalling lipoproteins in hypervirulent mycobacterial variants. Cell Microbiol 2011; 13: 692-704.
22. Bernut A, Herrmann JL, Kissa K et al. Mycobacterium abscessus cording prevents phagocytosis and promotes abscess formation. Proc Natl Acad Sci USA 2014; 111: E943-52.
23. Catherinot E, Clarissou J, Etienne G et al. Hypervirulence of a rough variant of the Mycobacterium abscessus type strain. Infect Immun 2007; 75:1055-8.
24. Moore M, Frerichs JB. An unusual acid-fast infection of the knee with subcutaneous, abscess-like lesions of the gluteal region; report of a case with a study of the organism, Mycobacterium abscessus, n. sp. J Invest Dermatol 1953; 20: 133-69.
25. Medjahed H, Reyrat JM. Construction of Mycobacterium abscessus defined glycopeptidolipid mutants: comparison of genetic tools. Appl Environ Microbiol 2009; 75: 1331-8.
26. Clinical and Laboratory Standards Institute. Susceptibility Testing of Mycobacteria, Nocardiae, and Other Aerobic Actinomycetes-Second Edition: Approved Standard M24-A2. CLSI, Wayne, PA, USA, 2011.
27. Ehmann DE, Jahic H, Ross PL et al. Avibactam is a covalent, reversible, non-β-lactam β-lactamase inhibitor. Proc Natl Acad Sci USA 2012; 109:11663-8.
28. Sarkar S, Sarkar D. Potential use of nitrate reductase as a biomarker for the identification of active and dormant inhibitors of Mycobacterium tuberculosis in a THP1 infection model. J Biomol Screen 2012; 17: 966-73.
29. Ehmann DE, Jahic H, Ross PL et al. Kinetics of avibactam inhibition against class A, C, and D β-lactamases. J Biol Chem 2013; 288: 27960-71.
30. Hugonnet JE, Blanchard JS. Irreversible inhibition of the Mycobacterium tuberculosis β-lactamase by clavulanate. Biochemistry 2007; 46: 11998-2004.
31. Xu H, Hazra S, Blanchard JS. NXL104 irreversibly inhibits the β-lactamase from Mycobacterium tuberculosis. Biochemistry 2012; 51:4551-7.
32. Lavollay M, Fourgeaud M, Herrmann JL et al. The peptidoglycan of Mycobacterium abscessus is predominantly cross-linked by L,D-transpeptidases. J Bacteriol 2011; 193: 778-82.
33. Buyck J, Luyck C, Van Bambeke F et al. Activity and phramacodynamic (PD) evaluation of ceftazidime-avibactam (CAZ-AVI) against extracellular and intracellular forms of CAZ-susceptible and CAZ-resistant Pseudomonas aeruginosa (PA). In: Abstracts of the Fifty-first Interscience Conference on Antimicrobial Agents and Chemotherapy, Denver, CO, 2013. Abstract A-1021. American Society for Microbiology, Washington, DC, USA.
34. Bernut A, Le Moigne V, Lesne Tet al. In vivo assessment of drug efficacy against Mycobacterium abscessus using the embryonic zebrafish test system. Antimicrob Agents Chemother 2014; 58: 4054-63.
35. Fukasawa M, Sumita Y, Harabe ET et al. Stability of meropenem and effect of 1 b-methyl substitution on its stability in the presence of renal dehydropeptidase I. Antimicrob Agents Chemother 1992; 36: 1577-9.
36. England K, Boshoff HI, Arora K et al. Meropenem-clavulanic acid shows activity against Mycobacterium tuberculosis in vivo. Antimicrob Agents Chemother 2012; 56: 3384-7.
37. Riccobene TA, Su SF, Rank D. Single-and multiple-dose study to determine the safety, tolerability, and pharmacokinetics of ceftaroline fosamil in combination with avibactam in healthy subjects. Antimicrob Agents Chemother 2013; 57: 1496-504.
38. Vazquez JA, Gonzalez Patzan LD, Stricklin D et al. Efficacy and safety of ceftazidime-avibactam versus imipenem-cilastatin in the treatment of complicated urinary tract infections, including acute pyelonephritis, in hospitalized adults: results of a prospective, investigator-blinded, randomized study. Curr Med Res Opin 2012; 28: 1921-31.
39. Lucasti C, Popescu I, Ramesh MK et al. Comparative study of the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infections in hospitalized adults: results of a randomized, double-blind, Phase II trial. J Antimicrob Chemother 2013; 68: 1183-92.
40. Nicolau DP, Siew L, Armstrong J et al. Concentration of avibactam (AVI) and ceftazidime (CAZ) in plasma and epithelial lining fluid (ELF) in healthy volunteers. In: Abstracts of the Fifty-third Interscience Conference on Antimicrobial Agents and Chemotherapy, Denver, CO, USA, 2013. Abstract A-1027. American Society for Microbiology, Washington, DC, USA.
41. Dallow J, Otterson LG, Huband MD et al. Microbiological interaction studies between ceftazidime-avibactam and lung surfactant and between ceftazidime-avibactam and antibacterial agents of other classes. Int J Antimicrob Agents 2014; 44: 552-6.